Dr Manoj Raghavan BA Hons., MBBS, PhD, FRCPath (Haematology); MRCP, CCST

Dr Manoj Raghavan

Department of Cancer and Genomic Sciences
Clinical Senior Lecturer
Honorary Consultant Haematologist

Contact details

Telephone
+44 (0)121 371 4476
Fax
44 (0)121 371 4486
Email
m.raghavan@bham.ac.uk
Twitter
@HaemOnc
View my research portal
Address
Centre for Clinical Haematology
Queen Elizabeth Hospital
Mindelsohn Way
Birmingham
B15 2TH

Manoj Raghavan is a consultant haematologist based at the Centre for Clinical Haematology. Manoj has a strong interest in myeloid malignancies, and the molecular and genetic basis of myeloid diseases. 

A major focus is the use of genomics for diagnostics and Precision Medicine in haematological malignancies and the application of genomic analysis through the Genomic Tumour Advisory Boards and West Midlands, Oxford and Wessex Genomics Laboratory Hub.

He collaborates with Professor Constanze Bonifer and Professor Peter Cockerill on acute myeloid leukaemia (AML), Dr Paloma Garcia on myelodysplastic syndromes (MDS) and Dr Rui Monteiro on bone marrow failure in the Department of Cancer and Genomic Sciences.

In December 2020, Manoj was appointed to the post of Precision Medicine Theme Lead for the Birmingham Experimental Cancer Medicine Centre (ECMC) . 

He is a member of the NCRI Haemato-oncology MDS sub-group and is co-Chief Investigator on the upcoming REPAIR-MDS trial in low/ intermediate risk MDS. Manoj is also chair of the British Society for Haematology Genomics Working Group, which aims to promote and provide guidelines and education to haematologists and biomedical scientists.

Qualifications

2008 August -  PhD, University of London - 'High-resolution genome-wide single nucleotide polymorphism mapping in acute myeloid Leukaemia'.

2004 August -  CCST Haematology 

2002 November - FRCPath (Haematology) 

1998 July - MRCP (UK) 

1988-1991 B.A. (Hons.) Trinity College, Cambridge Medical Science



Biography

Following an undergraduate medical degree at the University of Cambridge, Manoj graduated in Medicine from St George’s Hospital Medical School in 1994, and went on to train in haematology at University College Hospital, London.  He then carried out a PhD at Barts and the London School of Medicine and Dentistry, completing his studies in 2008. He was recruited to Birmingham in late 2010, taking up the post of Clinical Senior Lecturer at University of Birmingham, and Consultant Haematologist at University Hospitals Birmingham.

In his role as Birmingham ECMC Precision Medicine Theme Lead, Manoj is seeking to make early phase trials available to patients with targeted mutations, utilising clinical analysis of Next Generation Sequencing. He brings invaluable genomics expertise drawn from his role as chair of the West Midlands Genomic Tumour Advisory Board  for Haemato-oncology, Sarcoma, Neuro-oncology, Paediatrics and Cancer of Unknown Primary.

In addition to leading his own research group, Manoj is a member of the Myelodysplastic Syndrome (MDS) subgroup of the NCRI Haematology Oncology Clinical Studies Group.

Teaching

  • B.Sc. in Biomedical Sciences – Lecturer for Vascular Biology and Haematology, Cancer Pathogenesis and Treatment, New Targets and Drugs in Cancer Therapy modules.
  • Medicine and Surgery MBChB – Haematology teaching (lectures, tutorials)
  • Module lead for Haemato-oncology module for the MSc in Clinical Oncology 
  • Module lead for Haematology and Infection module and lecturer on Cancer: Pathology and Therapy module for the B Med Sc Intercalated degree 

Research

Clinical collaborations with University of Birmingham groups involved with molecular and cellular aspects of haematopoiesis: Professor Constanze Bonifer, Professor Peter Cockerill, Dr Paloma Garcia, Professor Chris Bunce , Dr Farhat Khanim, Dr Rui Monteiro.

Clinical collaborations with Dr Joanne Mason of West Midlands, Oxford and Wessex Genomics Laboratory Hub in genetic diagnostics.  

NCRI Haemato-oncology MDS sub-group member since 2011.

Co-Chief Investigator (CI) for Repair MDS (Bloodwise funded).

Local Principle Investigator (PI) for NCRI AML19 trial.

Local PI for BRIGHT study (glasdegib with chemotherapy) -  phase III randomised trial in AML

Local and national PI for Celgene PASS lenalidomide MDS del(5q) registry study.

Funding

2020: Repurposed drugs to improve haematological responses in Myelodysplastic Syndromes (MDS) - £998,110.64 Blood cancer UK 

July 2015: Mechanistic insights into aberrant transcriptional programming in acute myeloid leukaemia, Co-applicant (Lead Professor Constanze Bonifer) £1,543,859 Bloodwise

December 2013: Characterisation of the immune sequelae of post-transplant azacitidine and lenalidomide in patients with relapsed AML. Co-applicant (Lead Professor Charlie Craddock), £75,985 Bloodwise

Research Centres

Other activities

Clinical Roles at Queen Elizabeth Hospital Birmingham

  • Clinical lead for myeloid malignancies (acute myeloid leukaemia, myelodysplastic syndrome, myeloproliferative neoplasias)
  • Haematology-oncology MDT core member.
  • Diagnostic reporting for MIRHO (Midlands Integrated Regional Haemato-Oncology diagnostics service), with lead role in molecular genetics.
  • Member of HaemOnc NGS diagnostic MDT for West Midlands Regional Genetics Laboratory .
  • Member of MIRHO MDT reporting team.

Publications

Killick S. B. et al (Raghavan M. contributing author) on behalf of the British Society for Haematology. Guidelines for the diagnosis and evaluation of prognosis of adult myelodysplastic syndromes (DOI: 10.1111/bjh.17621) British Journal of Haematology. 2021 June 16 

Killick S. B. et al (Raghavan M. contributing author) Guidelines for the management of adult myelodysplastic syndromes (DOI: 10.1111/bjh.17612). British Journal of Haematology. 2021 June 27

Duncan N., Deekes N., FitzGerald D., Ng T. W T., Raghavan M. Models of care for chronic myeloid leukemia patients during the COVID-19 pandemic in the United Kingdom: Changes in patient attitudes to remote consultations and future implications (DOI: 10.1002.jha2.220) eJHaem. 2021 May 14 

Vilaplana-Lopera N. et al (Raghavan M. contributing author) Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells (DOI: 10.1101/2021.01.21.427406). Pre print bioRxiv. 2021 Jan 21. 

Milojkovic D. et al (Raghavan M. contributing author) Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study (DOI: 10.1111/bjh.16733). British Journal of Haematology. 2020 May 24 

Oldreive C.E., Byrd P. J., Stewart G. S., Taylor A. J., Farhat S., Skowronska A., Smith E., Raghavan M., Ranic D., Dokmanovic L., Klokie S., Davies N., Kwok M., Pratt G., Panesha S., Moss P., Stankovic T. and Taylor M. PALB2 variant status in haematological malignancies - a potential therapeutic target? (DOI:10.1080/10428194.2018.1551539). Leukemia & Lymphoma, 2019 Jan 7 

Craddock C, Raghavan M. Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant? (DOI: 10.1097/MOH.0000000000000482). Current Opinion in Hematology, 2019 March

Assi S.A., Imperato M.R., Coleman D. J. L., Pickin A., Potluri S., Ptasinska A., Chin P. S., Blair H., Cauchy P., James S. R., Zacarias-Cabeza J., Gilding L. N., Beggs A., Clokie S., Loke J. C., Jenkin P., Uddin A., Delwel R., Richards S. J., Raghavan M., Griffiths M. J., Heidenreich O., Cockerill P. N., Bonifer C. Subtype-specific regulatory network rewiring in acute myeloid leukemia (DOI:10.1038/s41588-018-0270-1). Nature Genetics. Epub ahead of print, 2018 Nov 12

Bayley R., Blakemore D., Cancian L., Dumon S., Volpe G., Ward C., Almaghrabi R., Gujar J., Reeve N., Raghavan M., Higgs M. R., Stewart G. S., Petermann E., García P. MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells (DOI: 10.1158/0008-5472.CAN-18-0273). Cancer Research. Epub 2018 Aug 6 

Craddock C. F., Houlton A. E., Quek L. S., Ferguson P., Gbandi E., Roberts C., Metzner M., Garcia-Martin N., Kennedy A., Hamblin A., Raghavan M. ... Paresh Vyas et al. Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature (DOI:10.1158/1078-0432.CCR-17.1423) Clinical Cancer Research. 2017 Nov 1

Cardoso S. R., Ellison A. C. M., Walne A. J., Cassiman D., Raghavan M. … Dokal I. Myelodysplasia and liver disease extend the spectrum of RTEL1 related telomeropathies (DOI: 0.3324/haematol.2017.167056);Haematologica. 2017 Aug 

Loke J, Assi S. A., Imperato M. R., Ptasinska A., Cauchy P. … Bonifer C. et al. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML (DOI:10.1016/j.celrep.2017.05.005); Cell Reports. 2017 May 23

Malaker S. A., Penny S. A., Steadman L. G., Myers P. T., Loke J. C., Raghavan M., Bai D. L., Shabanowitz J., Hunt D. F., Cobbold M. Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia (DOI: 10.1158/2326-6066.CIR-16-0280) Cancer Immunological Research. Epub 2017 March 17 

Loke, J., Akiki, S., Borrow, J., Ewing, J., Bokhari, S., Chandra, D., Arrazi, J., Hazlewood, P., Arthur, K., Walsh, J., Membwange, Y., Wandroo, F., Watts, A., Borg, A., Brock, K., Ferguson, P., Craddock, C., Griffiths, M. & Raghavan, M. Acquired Isodisomy on Chromosome 13 at diagnosis results in impaired overall survival in Patients with FLT3-ITD mutant Acute Myeloid Leukaemia (DOI: 10.1038/leu.2015.148.). Leukemia. Epub 2015 Jun 19

View all publications in research portal